Financière de Tubize SA Revenue Q/Q
What is the Revenue Q/Q of Financière de Tubize SA?
The Revenue Q/Q of Financière de Tubize SA is -100.00%
What is the definition of Revenue Q/Q?
Quarterly revenue growth, year over year, is the increase of a company’s revenue compared to the performance in the corresponding quarter of a previous year expressed as a percentage.
quarterly growth yoy (year over year)
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Revenue Q/Q of companies in the Health Care sector on EURONEXT compared to Financière de Tubize SA
What does Financière de Tubize SA do?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Companies with revenue q/q similar to Financière de Tubize SA
- Diamcor Mining has Revenue Q/Q of -100.29%
- Jupiter European Opportunities Trust Plc has Revenue Q/Q of -100.26%
- ICS Global has Revenue Q/Q of -100.22%
- Treasure ASA has Revenue Q/Q of -100.10%
- Sentry Select Primary Metals has Revenue Q/Q of -100.06%
- Candy Club has Revenue Q/Q of -100.03%
- Financière de Tubize SA has Revenue Q/Q of -100.00%
- Arcotech has Revenue Q/Q of -99.99%
- Prime Media has Revenue Q/Q of -99.99%
- Mineral Mountain Mining & Milling Co has Revenue Q/Q of -99.98%
- Wonderla Holidays has Revenue Q/Q of -99.98%
- Sanwaria Consumer has Revenue Q/Q of -99.97%
- Ezagoo has Revenue Q/Q of -99.95%